India · Delayed Price · Currency is INR Clean Science and Technology Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw revenue and margins decline due to weak demand, pricing pressure, and tariffs, but HALS business grew 55% YoY and new plants are expected to improve margins. CapEx projects are on track, and management remains focused on long-term growth despite ongoing market headwinds.
-
Revenue and profit declined due to lower volumes and competitive pressures, but EBITDA margins remained robust. Health segment showed strong sequential growth, new products were commercialized, and capacity expansions are underway. Market uncertainties and tariffs continue to pose risks.
-
Q1 FY26 saw resilient margins despite a 9% sequential revenue drop, with record-high standalone EBITDA margin over 46%. New product launches and CapEx investments are set to drive growth, though guidance is moderated to 15%-18% EBITDA growth for FY26.
Fiscal Year 2025
-
Record sales volumes and new product launches drove double-digit revenue and EBITDA growth, with HALS segment tripling in volume and major CAPEX investments supporting future expansion. FY 2026 guidance targets strong revenue growth, margin stability, and further commercialization of new products.
-
Q3FY25 delivered strong volume-led growth and robust margins, with all major product lines commercialized and global distribution networks established. New products and capacity expansions are set to drive further revenue and margin improvements in FY26.
-
Q2 FY25 delivered strong volume-led growth, with sales up 26% and PAT up 30% year-over-year. New product launches, capacity ramp-ups, and major CapEx projects are set to drive further expansion, while margins remain robust despite raw material cost pressures.
-
Q1 FY25 delivered 16% year-over-year sales growth and 23% PAT growth, driven by strong volumes and margin expansion. New HALS products were commercialized, CapEx projects advanced, and capacity utilization is set to rise, supporting future profitability.